NYSE:LLY
Eli Lilly & Co. (LLY-N)
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
Apr 16, 2025, 12:00 amThis summary was created by AI, based on 55 opinions in the last 12 months.
Eli Lilly & Co. (LLY) has emerged as a strong player in the healthcare sector, particularly driven by its diabetes and obesity treatments which continue to propel sales and earnings forecasts. Analysts emphasize its robust growth profile, potential in the weight-loss drug market, and a strong pipeline that includes expansions into broader areas like inflammatory bowel diseases and Alzheimer's treatments. Despite its high valuation metrics, many experts maintain a positive outlook on LLY's ability to innovate and capture market share from competitors. The company's significant investments in manufacturing, marked momentum in stock performance, and excellent fundamentals underpin their hopeful projections for future growth. However, some analysts caution about its current valuation, viewing it as high relative to its peers, alongside concerns regarding future competition and the sustainability of its growth trajectory.
Best among the weight-loss drugs, more effective than its peers. Also, the oral version will be a game-changer. LLY is gaining market share as its manufacturing ramps up. Shares are flat and need a catalyst, possibly on Aug. 7 with earnings. Their oncology platform is also doing well. He expects their revenues to double by 2030, based on 25-30% compounded growth.
Premium contentThis big pharma company has a host of weight loss GLP-1 medications that it will soon release progress reports on later this month, some of which have already received approvals to develop. It trades at 27x forward earnings and supports a 77% ROE. We recommend setting a stop-loss at $703, looking to achieve $987 -- upside potential over 20%. Yield 0.7%
(Analysts’ price target is $987.22)The more successful of the GLP-1 stocks compared to NVO. Decent entry point. Trades in the 30s on forward PE, so there's a strong expectation of prescription growth; every reason to believe that's going to happen.
Be cautious on position size; don't be aggressive. Stock was down 10% yesterday because NVO made a deal with CVS to become its prime recommended product for obesity. So NVO is starting to compete more on price.
Plethora of ideas. Part of the story on cancer. Weight-loss drug is in the lead, and a pill instead of injection is the ultimate goal. Earnings from weight loss will double in 3 years, and then they still have all the other drugs in the pipeline. Yield is 0.70%.
(Analysts’ price target is $996.37)
Eli Lilly & Co.(LLY-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 24
Neutral - Hold Signals / Votes : 8
Bearish - Sell Signals / Votes : 8
Total Signals / Votes : 40
Eli Lilly & Co.(LLY-N) Frequently Asked Questions
What is Eli Lilly & Co. stock symbol?
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
Is Eli Lilly & Co. a buy or a sell?
In the last year, 40 stock analysts published opinions about LLY-N. 24 analysts recommended to BUY the stock. 8 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Is Eli Lilly & Co. a good investment or a top pick?
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Why is Eli Lilly & Co. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Eli Lilly & Co. worth watching?
40 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
What is Eli Lilly & Co. stock price?
On 2025-08-08, Eli Lilly & Co. (LLY-N) stock closed at a price of $625.65.
A lot of the move down happened this week. Numbers were good -- earnings and revenue beat, guidance was good. Market really homed in on obesity pill disappointment (slightly less efficacy than a competitor's, 10% dropped out due to side effects). Now trades at 24x PE, with 19% growth.
Very cheap, but sentiment has become difficult and challenging. Long term, the demand for diabetes and obesity drugs is still there and will continue to grow. Industry-leading Alzheimer's drug in pipeline as well. Fortress-like balance sheet, really great cashflow.